A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Public ClinicalTrials.gov record NCT03652077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
Study identification
- NCT ID
- NCT03652077
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- Cervical Cancer
- Gastric Cancer
- Stomach Cancer
- Gastroesophageal Junction Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma
- Uveal Melanoma
- Merkel Cell Carcinoma
- Mesothelioma
- MSI
- Non-small Cell Lung Cancer
- NSCLC
- Ovarian Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Small Cell Lung Cancer
- Renal Cell Carcinoma
- RCC
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Mismatch Repair Deficiency
Interventions
- INCAGN02390 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2018
- Primary completion
- Aug 17, 2021
- Completion
- Aug 17, 2021
- Last update posted
- Nov 14, 2021
2018 – 2021
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinical and Research Institute | Los Angeles | California | 90025 | — |
| University of Mississippi | Jackson | Mississippi | 39216 | — |
| Hackensack Medical Center | Hackensack | New Jersey | 07601 | — |
| Carolina BioOncology | Huntsville | North Carolina | 28078 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03652077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03652077 live on ClinicalTrials.gov.